Fourth approved indication for ofatumumab in chronic lymphocytic leukemia
The Journal of Community and Supportive Oncology. 2016 November;14(11):447-449 | 10.12788/ jcso.0303
November 22, 2016|The Journal of Community and Supportive Oncology
The recent decision by the US Food and Drug Administration to approve ofatumumab in combination with fludarabine and cyclophosphamide in relapsed disease marks a fourth approved indication for this drug in patients with chronic lymphocytic leukemia (CLL). Ofatumumab is a fully human monoclonal antibody that targets the CD20 protein on the surface of B cells, first approved for the treatment of CLL back in 2009.
Click on the PDF icon at the top of this introduction to read the full article.
